Patent SG-11201804934P-A (SG)
Title: Novel Compounds
Inventor: KEMP MARK IAN
IPC: C07D471/04
Filed: 2016-12-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property , Organization M1111101110101011111 HO 111110111010111110011011010 HI MEV III 11 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/103614 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: STRATAGEM INTELLECTUAL PROPERTY C07D 403/12 (2006.01) CO7D 487/04 (2006.01) MANAGEMENT LIMITED; Meridian Court, Comber- CO7D 401/12 (2006.01) CO7D 207/09 (2006.01) ton Road, Tat, Cambridge CB23 2RY (GB). CO7D 403/14 (2006.01) A61K 31/4025 (2006.01) CO7D 413/12 (2006.01) A61K 31/407 (2006.01) (81) Designated States (unless otherwise indicated, for every CO7D 417/12 (2006.01) A61P 25/28 (2006.01) kind of national protection available): AE, AG, AL, AM, CO7D 417/14 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CO7D 471/04 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/GB2016/053971 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 16 December 2016 (16.12.2016) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 1522267.2 17 December 2015 (17.12.2015) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: MISSION THERAPEUTICS LIMITED TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [GB/GB]; Moneta (Building 280), Babraham Research TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Campus, Cambridge CB22 3AT (GB). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, — LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: KEMP, Mark Ian; C/o Mission Therapeutics SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Limited, Moneta (Building 280), Babraham Research Cam- = Cambridge CB22 3AT STOCKLEY, Martin pus, (GB). Lee; C/o Mission Therapeutics Limited, Moneta Published: (Building 280), Babraham Research Campus, Cambridge CB22 3AT — with international search report (Art. 21(3)) (GB). MADIN, Andrew; C/o Mission Therapeutics Lim- ited, Moneta (Building 280), Babraham Research Campus, _ Cambridge CB22 3AT (GB). = = = = = = (54) Title: Novel Compounds = = U = N ,. _ , N 1-1 . 7r M r'S 1 ',. 11 M 0 (I) 1-1 IN 1-1 (57) : The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating N enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochon- C drial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically ac - ceptable salt thereof, wherein R I ', R ib , R', R id , R 1 ', R if , R i g, R 2 , X, L and A are as defined herein.